Syros Pharmaceuticals, Inc. (SYRS)
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
$52.92M
Dr. Nancy A. Simonian M.D.
124.00
Cambridge, MA
Jun 30, 2016
-0.46
$-4.35
4.07
5.38
-1,060.53%
-1.81
-0.18
1.11
14.26
5.14
-24.68%
-40.89%
Similar stocks (18)
Crinetics Pharmaceuticals, Inc.
CRNX
IDEAYA Biosciences, Inc.
IDYA
Keros Therapeutics, Inc.
KROS
Syndax Pharmaceuticals, Inc.
SNDX
Stoke Therapeutics, Inc.
STOK
REGENXBIO Inc.
RGNX
Larimar Therapeutics, Inc.
LRMR
Black Diamond Therapeutics, Inc.
BDTX
Coherus BioSciences, Inc.
CHRS
Spero Therapeutics, Inc.
SPRO
Kronos Bio, Inc.
KRON
Passage Bio, Inc.
PASG
Kezar Life Sciences, Inc.
KZR
Surrozen, Inc.
SRZN
Bolt Biotherapeutics, Inc.
BOLT
RenovoRx, Inc.
RNXT
Pasithea Therapeutics Corp.
KTTA
Quoin Pharmaceuticals, Ltd.
QNRX
ETF Exposure (11)
iShares Micro-Cap ETF
IWC
0.01003%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (18)
Crinetics Pharmaceuticals, Inc.
CRNX
IDEAYA Biosciences, Inc.
IDYA
Keros Therapeutics, Inc.
KROS
Syndax Pharmaceuticals, Inc.
SNDX
Stoke Therapeutics, Inc.
STOK
REGENXBIO Inc.
RGNX
Larimar Therapeutics, Inc.
LRMR
Black Diamond Therapeutics, Inc.
BDTX
Coherus BioSciences, Inc.
CHRS
Spero Therapeutics, Inc.
SPRO
Kronos Bio, Inc.
KRON
Passage Bio, Inc.
PASG
Kezar Life Sciences, Inc.
KZR
Surrozen, Inc.
SRZN
Bolt Biotherapeutics, Inc.
BOLT
RenovoRx, Inc.
RNXT
Pasithea Therapeutics Corp.
KTTA
Quoin Pharmaceuticals, Ltd.
QNRX
ETF Exposure (11)
iShares Micro-Cap ETF
IWC
0.01003%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%